Q1 EPS Forecast for Soleno Therapeutics Raised by Analyst

Soleno Therapeutics, Inc. (NASDAQ:SLNO) – Analysts at Lifesci Capital boosted their Q1 2026 EPS estimates for Soleno Therapeutics in a research note issued to investors on Thursday, February 26th. Lifesci Capital analyst K. Dellorusso now anticipates that the company will earn $0.74 per share for the quarter, up from their previous forecast of $0.58. The consensus estimate for Soleno Therapeutics’ current full-year earnings is ($3.72) per share. Lifesci Capital also issued estimates for Soleno Therapeutics’ Q2 2026 earnings at $0.98 EPS, Q3 2026 earnings at $1.10 EPS, Q4 2026 earnings at $1.34 EPS and FY2026 earnings at $4.16 EPS.

Soleno Therapeutics (NASDAQ:SLNO) last posted its earnings results on Wednesday, February 25th. The company reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.16. The business had revenue of $91.73 million for the quarter, compared to analyst estimates of $88.55 million.

A number of other research analysts also recently commented on the company. Zacks Research downgraded Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 3rd. HC Wainwright reiterated a “buy” rating and issued a $120.00 target price (up from $110.00) on shares of Soleno Therapeutics in a report on Tuesday, January 20th. Wells Fargo & Company cut their target price on shares of Soleno Therapeutics from $114.00 to $110.00 and set an “overweight” rating for the company in a research note on Friday. TD Cowen reduced their target price on shares of Soleno Therapeutics from $120.00 to $85.00 and set a “buy” rating for the company in a report on Thursday. Finally, Wolfe Research set a $60.00 price target on shares of Soleno Therapeutics in a research report on Monday, January 12th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $108.38.

Soleno Therapeutics Stock Performance

SLNO stock opened at $39.07 on Monday. Soleno Therapeutics has a 12-month low of $32.63 and a 12-month high of $90.32. The stock’s 50 day simple moving average is $42.63 and its 200 day simple moving average is $53.13. The company has a current ratio of 5.80, a quick ratio of 5.55 and a debt-to-equity ratio of 0.11. The firm has a market cap of $2.02 billion, a P/E ratio of 169.88 and a beta of -3.16.

Hedge Funds Weigh In On Soleno Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Raymond James Financial Inc. purchased a new stake in shares of Soleno Therapeutics during the 2nd quarter worth about $25,000. Danske Bank A S bought a new position in Soleno Therapeutics during the third quarter valued at approximately $27,000. Nisa Investment Advisors LLC raised its position in Soleno Therapeutics by 287.8% during the second quarter. Nisa Investment Advisors LLC now owns 539 shares of the company’s stock valued at $45,000 after acquiring an additional 400 shares in the last quarter. Aster Capital Management DIFC Ltd acquired a new stake in Soleno Therapeutics in the third quarter valued at approximately $37,000. Finally, Global Retirement Partners LLC lifted its stake in Soleno Therapeutics by 519.0% in the fourth quarter. Global Retirement Partners LLC now owns 619 shares of the company’s stock valued at $29,000 after acquiring an additional 519 shares during the last quarter. 97.42% of the stock is currently owned by hedge funds and other institutional investors.

Key Soleno Therapeutics News

Here are the key news stories impacting Soleno Therapeutics this week:

• Positive Sentiment: Earnings beat and profitability: Soleno reported Q4 2025 EPS of $0.80 (vs. $0.64 consensus) and revenue of $91.73M (vs. $88.55M), and management highlighted achieving profitability — the core reason investors are bidding the stock up. Soleno Therapeutics, Inc. Q4 2025 Earnings Call Summary
• Neutral Sentiment: Full earnings/transcript availability: Multiple transcripts and call write-ups (Seeking Alpha, Yahoo) give investors detailed color on guidance, margins and cash flow — useful for conviction but not immediate catalysts. Q4 2025 Earnings Call Transcript Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Wells Fargo cut its price target slightly from $114 to $110 but kept an Overweight rating — this is a modest headwind but still signals strong upside from analysts. Wells Fargo price-target note
• Negative Sentiment: TD Cowen substantially lowered its target (from $120 to $85) despite maintaining a Buy rating — the larger cut adds downward pressure to headline analyst sentiment and may temper the rally. TD Cowen price-target change
• Negative Sentiment: Near-term volatility / profit-taking explained: Coverage and commentary note a sharp intraday decline (reported as ~10.8% in one write-up) after the earnings run-up — investors appear to be re‑rating the name on guidance details, forward EPS expectations, and valuation. Why SLNO Stock Is Down 10.80%

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.